Japanese regulators have approved an arthritis treatment developed by Genzyme Corp. The injection, called Synvisc, will be marketed by the Japanese company Teijin Pharma Ltd. and will be used to treat osteoarthritis of the knee.
Genzyme officials said that a recent study in Japan found that 30 million Japanese patients have osteoarthritis of the knee. Genzyme says Synvisc will be the first non-Japanese viscosupplement product approved in the country that can offer six months of pain relief with three injections. Genzyme plans to launch Synvisc in Japan by the end of this year.